# Isabl

Source: https://onco.cc/companies/isabl/  
OnCo record `isabl` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Isabl reads a tumour's whole genome and transcriptome instead of a small gene panel, and its software turns that into a report clinicians can use.

## Summary

Isabl, a Memorial Sloan Kettering spin-out, provides software and a CLIA laboratory for clinical whole-genome and whole-transcriptome sequencing of tumours, analysing the full range of mutations, structural variants, signatures and expression rather than a targeted panel, with applications in treatment planning, disease surveillance and biomarker discovery. It states it is the first to receive New York State approval for a whole-genome and transcriptome cancer test. Evidence of clinical utility beyond analytical validation is still accumulating.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- Tags: yc
- HQ: New York, NY
- Type: diagnostics
- Website: https://isabl.io

## Sources

- Y Combinator profile: https://www.ycombinator.com/companies/isabl
- Official website: https://isabl.io

## Connected records

- fronts: [Diagnostics & Biomarkers](https://onco.cc/fronts/diagnostics/)
- technologies: [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/), [RNA sequencing & expression profiling](https://onco.cc/technologies/rna-seq/), [Whole-exome & whole-genome sequencing](https://onco.cc/technologies/wes-wgs/)
- companies: [Y Combinator](https://onco.cc/companies/y-combinator/)

---
JSON: https://onco.cc/api/v1/entities/isabl.json